Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 1110-1120

  Polinski, Nicole K ^a,b   Gombash, Sara E ^c   Manfredsson, Fredric P ^a   Lipton, Jack W ^a   Kemp, Christopher J ^a   Cole Strauss, Allyson ^a   Kanaan, Nicholas M ^a   Steece Collier, Kathy ^a   Kuhn, Nathan C ^a   Wohlgenant, Susan L ^a   Sortwell, Caryl E ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Parkinson's disease; Striatum; Substantia nigra; Transduction; Viral vector

Indexed keywords

GREEN FLUORESCENT PROTEIN; MESSENGER RNA;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 5; ADULT; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; GFP GENE; GROUPS BY AGE; MALE; MESENCEPHALON; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FOLDING; RAT; SIGNAL TRANSDUCTION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; YOUNG ADULT; ANIMAL; DEPENDOPARVOVIRUS; FISCHER 344 RAT; GENE EXPRESSION REGULATION; GENE TRANSFER; GENE VECTOR; GENETIC RECOMBINATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT;

AGING; ANIMALS; DEPENDOVIRUS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; MALE; MESENCEPHALON; RATS, INBRED F344; RATS, SPRAGUE-DAWLEY; RECOMBINATION, GENETIC; RNA, MESSENGER;

EID: 84922805939     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.07.047     Document Type: Article

References (47)

1. Alemán C.L., Más R.M., Rodeiro I., Noa M., Hernández C., Menéndez R., Gámez R. Reference database of the main physiological parameters in Sprague-Dawley rats from 6-32 months. Lab. Anim. 1998, 32:457-466.
2. Bantel-Schall U., Hub B., Kartenbeck J. Endocytosis of adeno-associated virus type 5 leads to accumulation of virus particles in the Golgi compartment. J.Virol. 2002, 76:2340-2349.
3. Bartlett J.S., Wilcher R., Samulski R.J. Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J.Virol. 2000, 74:2777-2785.
4. Bartus R.T., Herzog C.D., Chu Y., Wilson A., Brown L., Siffert J., Johnson E.M., Olanow C.W., Mufson E.J., Kordower J.H. Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov. Disord. 2011, 28:27-36.
5. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson's disease. Nat. Genet. 2006, 38:515-517.
6. Blanpied T.A., Scott D.B., Ehlers M.D. Age-related regulation of dendritic endocytosis associated with altered clathrin dynamics. Neurobiol. Aging 2003, 24:1095-1104.
7. Burger C., Gorbatyuk O.S., Velardo M.J., Peden C.S., Williams P., Zolotukhin S., Reier P.J., Mandel R.J., Muzczka M. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1,2, and 5 display differential efficacy and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 2004, 10:302-317.
8. AAV2-GDNF for Advanced Parkinson's Disease 2013, ClinicalTrials.gov, Available at:. http://www.clinicaltrials.gov/ct2/show/NCT01621581.
9. Collier T.J., Sortwell C.E., Daley B.F. Diminished viability, growth, and behavioral efficacy of fetal dopamine neuron grafts in aging rats with long-term dopamine depletion: an argument for neurotrophic supplementation. J.Neurosci. 1999, 19:5563-5573.
10. Collier T.J., Kanaan N.M., Kordower J.H. Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat. Rev. Neurosci. 2011, 12:359-366.
11. D'Angelo M.A., Raices M., Panowski S.H., Hetzer M.W. Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells. Cell 2009, 136:284-295.
12. Di Pasquale G., Davidson B.L., Stein C.S., Martins I., Scudiero D., Monks A., Chiorini J.A. Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 2003, 9:1306-1312.
13. Ding W., Zhang L., Yan Z., Engelhardt J.F. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 2005, 12:873-880.
14. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., Ravina B.M., Schifitto G., Siderowf A., Tanner C.M. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
15. Emborg M.E., Miorano J., Raschke J., Bondarenko V., Zufferey R., Peng S., Ebert A.D., Joers V., Roitberg B., Holden J.E., Koprich J., Lipton J., Kordower J.H., Aebischer P. Response of aged parkinsonian monkeys to invivo gene transfer of GDNF. Neurobiol. Dis. 2009, 36:303-311.
16. Gao J., Miao H., Xiao C.H., Sun Y., Du X., Yuan H.H., Yu H.L., Gao D.S. Influence of aging on the dopaminergic neurons in the substantia nigra pars compacta of rats. Curr. Aging Sci. 2011, 4:19-24.
17. Gao L., Hidalgo-Figueroa M., Escudero L.M., Diaz-Martin J., Lopez-Barneo J., Pascual A. Age-mediated transcriptomic changes in adult mouse substantia nigra. PLoS One 2013, 8:e62456.
18. Gash D.M., Zhang Z., Ovadia A., Cass W.A., Yi A., Simmerman L., Russell D., Martin D., Lapchak P.A., Collins F., Hoffer B.J., Gerhardt G.A. Functionalrecovery in parkinsonian monkeys treated with GDNF. Nature 1996, 380:252-255.
19. Gasmi M., Brandon E.P., Herzog C.D., Wilson A., Bishop K.M., Hofer E.K., Cunningham J.J., Printz M.A., Kordower J.H., Bartus R.T. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol. Dis. 2007, 27:67-76.
20. Gombash S.E., Manfredsson F.P., Mandel R.J., Collier T.J., Fischer D.L., Kemp C.J., Kuhn N.M., Wohlgenant S.L., Fleming S.M., Sortwell C.E. Striatonigral pleiotrophin overexpression provides superior protection compared to overexpression in both striatonigral and nigrostriatal pathways. Gene Ther 2014, 11. 10.1038/gt.2014.42.
21. Gombash S.E., Manfredsson F.P., Kemp C.J., Kuhn N.C., Fleming S.M., Egan A.E., Grant L.M., Ciucci M.R., MacKeigan J.P., Sortwell C.E. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system. PLoS One 2013, 8:e81426.
22. Gombash S.E., Lipton J.W., Collier T.J., Madhavan L., Steece-Collier K., Cole-Strauss A., Terpstra B.T., Spieles-Engemann A.L., Daley B.F., Wohlgenant S.L., Thompson V.B., Manfredsson F.P., Mandel R.J., Sortwell C.E. Striatal pleiotrophin overexpression provides functional and morphological neuroprotection in the 6-hydroxydopamine model. Mol. Ther. 2012, 20:544-554.
23. Hansen J., Qing K., Srivastava A. Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 2001, 4:289-296.
24. Herzog C.D., Brown L., Gammon D., Kruegel B., Lin R., Wilson A., Bolton A., Printz M., Gasmi M., Bishop K.M., Kordower K.H., Bartus R.T. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurtrin to the monkey nigrostriatal system support CERE-120 for Parkinson's disease. Neurosurgery 2008, 64:602-613.
25. Johnson J., Samulski R. Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J.Virol. 2009, 83:2632-2644.
26. Klein R.L., Dayton R.D., Diaczynsky C.G., Wang D.B. Pronounced microgliosis and neurodegeneration in aged rats after tau gene transfer. Neurobiol. Aging 2010, 31:2091-2102.
27. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., McBride J., Chen E.Y., Palfi S., Roitberg B.Z., Brown W.D., Holden J.E., Pyzalski R., Taylor M.D., Carvey P., Ling Z., Trono D., Hantraye P., Déglon N., Aebischer P. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
28. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko N. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nat. Genet. 2006, 38:518-520.
29. Lee C., Weindruch R., Prolla T.A. Gene-expression profile of the ageing brain in mice. Nat. Genet. 2000, 25:294-297.
30. Marks W.J., Bartus R.T., Siffert J., Davis C.S., Lozano A., Boulis N., Vitek J., Stacy M., Turner D., Verhagen L., Bakay R., Watts R., Guthrie B., Jankovic J., Sompson R., Tagliati M., Alterman R., Stern M., Baltuch G., Starr P.A., Larson P.S., Ostrem J.L., Nutt J., Kieburtz K., Kordower J.H., Olanow C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind randomized, controlled trial. Lancet 2010, 9:1164-1172.
31. Meier O., Greber U.F. Adenovirus endocytosis. J.Gene Med. 2004, 6(Suppl 1):S152-S163.
32. Park J., Park W., Cho K., Kim D., Jhun B., Kim S., Park S.C. Down-regulation of amphiphysin-1 is responsible for reduced receptor-mediated endocytosis in the senescent cells. FASEB J. 2001, 15:1625-1627.
33. Pfaffl M.W., Horgan G.W., Dempfle L. Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002, 30:e36.
34. Piltonen M., Bespalov M.M., Ervasti D., Matilainen T., Sidorova Y.A., Rauvala H., Saarma M., Mannisto P.T. Heparin-binding determinants of GDNF reduce its tissue distribution but are beneficial for the protection of nigral dopaminergic neurons. Exp. Neurol. 2009, 219:499-506.
35. Ryazanov A.G., Nefsky B.S. Protein turnover plays a key role in aging. Mech. Ageing Dev. 2002, 123:207-213.
36. Sasaki T., Akimoto Y., Sato Y., Kawakami H., Hirano H., Endo T. Distribution of sialoglycoconjugates in the rat cerebellum and its change with age. J.Histochem. Cytochem. 2002, 50:1179-1186.
37. Sato Y., Akimoto Y., Kawakami H., Hirano H., Endo T. Location of sialoglycoconjugates containing Sia(alpha)2-3Gal and Sia(alpha)2-6Gal groups in the rat hippocampus and the effect of aging on their expression. J.Histochem. Cytochem. 2001, 49:1311-1319.
38. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 2008, 3:1101-1108.
39. Schultz B.R., Chamberlain J.S. Recombinant adeno-associated virus transduction and integration. Mol. Ther. 2008, 16:1189-1199.
40. Smith C.B., Sun Y., Sokoloff L. Effects of aging on regional rates of cerebral protein synthesis in the Sprague-Dawley rat: examination of the influence of recycling of amino acids derived from protein degradation into the precursor pool. Neurochem. Int. 1995, 27:407-416.
41. Sortwell C.E., Camargo M.D., Pitzer M.R., Gyawali S., Collier T.J. Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval. Exp. Neurol. 2001, 169:23-29.
42. Stocchi F., Olanow C.W. Obstacles to the development of a neuroprotective therapy for Parkinsons's disease. Mov. Disord. 2013, 28:3-7.
43. Takahashi M., Yamada T., Nakajima S., Yamamoto T., Okada H. The substantia nigra is a major target for neurovirulent influenza A virus. J.Exp. Med. 1995, 181:2161-2169.
44. Walters R.W., Yi S.M., Keshavjee S., Brown K.E., Welsh M.J., Chiorini J.A., Zabner J. Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J.Biol. Chem. 2001, 276:20610-20616.
45. Wang F., Flanagan J., Su N., Wang L., Bui S., Nielson A., Wu X., Vo H.T., Ma X.J., Luo Y. RNAscope: a novel in situ RNA platform for formalin-fixed, paraffin-embedded tissues. J.Mol. Diagn. 2012, 14:22-29.
46. Wu K., Meyers C.A., Guerra N.K., King M.A., Meyer E.M. The effects of rAAV2-mediated NGF gene delivery in adult and aged rats. Mol. Ther. 2004, 9:262-269.
47. Zolotukhin S., Byme B.J., Mason E., Zolotukhin E., Potter M., Chesnut K., Summerford C., Samulski R.J., Muzyczka N. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 1999, 6:973-985.